Oxford BioMedica

United Kingdom
Saint Neots, England, United Kingdom, OX4 6L

Company profile

Oxford BioMedica company profile

Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture. Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body. Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes. Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.

Business identity

Contact email
[email protected]
Phone number
+4401865783000
Operating status
Active
Company type
For Profit
Employee range
501-1,000 employees
Revenue range
$10M-$100M
Founded
1995-01-01, Year

Headquarters

Postal code
OX4 6L
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
6
Total equity funding
$149.1M
Last funding
Post IPO Debt / $60M / 2025-08-01
Last equity funding
Post IPO Equity / $68.1M
Investors
4
Lead investors
2
Founders
2
Articles
164
Exited on
2001-04-17

Founders and investors

Founders

Alan KingsmanSusan Kingsman

Lead investors

Oaktree Capital ManagementSerum Institute of India Pvt. Ltd.

Investors

Innovate UKNovo HoldingsOaktree Capital ManagementSerum Institute of India Pvt. Ltd.